5450 Chemin de la Côte-des-Neiges

Suite 522

Montréal, Qc

H3T 1Y6

514-282-4523

info@exactis.ca

  • White LinkedIn Icon
Send Us a Message

© 2018 by Exactis Innovation

Media are welcome to contact Exactis for information about our operations or as a resource for more general stories about cancer clinical research in Canada.

 

Click here to contact us via email and we will answer your request promptly.

July 29, 2019

Exactis Innovation is pleased to award $1M CDN to catalyze clinical research on innovative precision oncology therapeutics in Canada. This grant will support a multi-centre clinical trial in the Exactis research network comprising eleven premier cancer care institution...

June 12, 2019

The TRICIA Study, a research project pairing molecular data with artificial intelligence, was awarded funding of $1.6 million this week by the Biopharmaceutical Research Consortium CQDM, the Ministère de l’Économie et de l’Innovation of the Government of Quebec, and th...

June 3, 2019

We would like to congratulate everyone in the PMT network. An important milestone was reached with more than 4000 participants enrolled. In the past 3 years, we have grown at an impressive rate. It took the network 14 months to reach 1000 patients; today we were able t...

March 27, 2019

We are pleased to share an article on Precision Oncology and the Exactis PMT initiative appearing on www.personalhealthnews.ca, and printed in the April 2019 edition of Maclean’s Magazine, as part of a Mediaplanet special interest "Advancements in Cancer Care & Rare Di...

February 13, 2019

Exactis Innovation is pleased to formally announce the launch of the Exactis Innovation Investigator-Initiated Trial (IIT) Grant Competition.

In alignment with the Exactis Mission to accelerate precision oncology by matching specific molecular or clinical profiles to no...

September 12, 2018

MRM Proteomics Inc. is partnering with Exactis Innovation to develop and validate a clinical proteomic test that will provide clinicians and scientists with the ability to identify immune signatures and tumour mutation profiles to better match patients with the most ef...

Please reload